Allist developed an oral disintegrated formulation of proton pump inhibitor for treatment of ulcer . An application for clinical trail has been filed to SFDA for approval in March of this year.

For mutual benefits and development, Allist and Conba collaborate with each other to produce the new product. Hangzhou Conba Pharmaceuticals Ltd. with the most advanced equipment and techniques is a new drug and formulation manufacture base. It is one subsidiary company of Zhejiang Conba Pharmaceuticals Limited Co. It strives for producing and selling new formulation of drugs and focuses its main strengths in new drug formulations products, like delayed-releasing, controlled-releasing and fast-releasing formulations. Hangzhou Conba is located in Binjiang Science and Technology Economic Park in Hangzhou Hi-tech Development Zone with an area of 138 mu and its investment of registration is 120million yuan. In Oct. 2003, it was granted with a GMP certification.

The new drug created by the joint efforts of Shanghai Allist and Hangzhou Conba will come into the market in 2008.